Investors might want to bet on Alnylam Pharmaceuticals (ALNY) , as earnings estimates for this company have been showing solid improvement lately. The stock has already gained solid short-term price momentum, and this trend might continue with its still improving earnings outlook.Analysts' growing optimism on the earnings prospects of this RNA interference drug developer is driving estimates higher, which should get reflected in its stock price. After all, empirical research shows a strong correlation betwe ...

Core Viewpoint - Truist has raised the price target for Alnylam Pharmaceuticals (ALNY) to $535 from $459 while maintaining a Buy rating ahead of the company's Q3 results [1] Group 1: Sales Estimates - The Q3 sales estimate for Amvuttra has been increased to $690 million [1] - The upward revision in forward estimates reflects strong early adoption and more rapid adoption as a first-line agent than previously expected [1] Group 2: Market Insights - Feedback from prescribers indicates that extracardiac manifestations of ATTR-CM are more widespread than previously appreciated [1]

Core Viewpoint - Momentum investing focuses on following a stock's recent price trends, aiming to buy high and sell higher, with the expectation that established trends will continue [1] Company Overview: Alnylam Pharmaceuticals (ALNY) - Alnylam Pharmaceuticals currently holds a Momentum Style Score of A, indicating strong momentum characteristics [2] - The company has a Zacks Rank of 2 (Buy), suggesting a favorable outlook based on historical performance metrics [3] Performance Metrics - Over the past week, ALNY shares increased by 0.9%, while the Zacks Medical - Biomedical and Genetics industry declined by 0.34% [5] - In the last quarter, ALNY shares rose by 44.29%, and over the past year, they gained 63.33%, significantly outperforming the S&P 500, which increased by 6.33% and 14.66% respectively [6] - The average 20-day trading volume for ALNY is 1,102,099 shares, indicating a bullish trend when combined with rising stock prices [7] Earnings Outlook - In the past two months, three earnings estimates for ALNY have been revised upwards, while none have been lowered, raising the consensus estimate from $3.35 to $3.98 [9] - For the next fiscal year, two estimates have increased, while one has decreased, reflecting a generally positive earnings outlook [9] Conclusion - Given the strong performance metrics and positive earnings outlook, ALNY is positioned as a promising investment opportunity with a Momentum Score of A [11]

Core Insights - Investors in Alnylam Pharmaceuticals, Inc. (ALNY) should monitor stock movements due to significant implied volatility in the options market, particularly the Dec 19, 2025 $140.00 Put option [1] Company Overview - Alnylam Pharmaceuticals holds a Zacks Rank 2 (Buy) in the Medical - Biomedical and Genetics industry, which is in the top 36% of the Zacks Industry Rank [3] - Over the last 60 days, three analysts have raised their earnings estimates for the current quarter, increasing the Zacks Consensus Estimate from earnings of $1.14 per share to $1.71 [3] Market Sentiment - The high implied volatility suggests that options traders anticipate a significant price movement for Alnylam Pharmaceuticals shares, potentially indicating an upcoming event that could lead to a major rally or sell-off [2][3] - Options traders often seek high implied volatility options to sell premium, aiming to benefit from the decay of options value if the underlying stock does not move as much as expected [4]

Company Overview - Alnylam Pharmaceuticals (ALNY) is a notable stock within the Medical sector, which consists of 956 individual stocks and ranks 6 in the Zacks Sector Rank [2] - The company is part of the Medical - Biomedical and Genetics industry, which includes 470 companies and currently ranks 94 in the Zacks Industry Rank [6] Performance Metrics - Alnylam Pharmaceuticals has achieved a year-to-date return of approximately 97.6%, significantly outperforming the average return of -0.1% for Medical companies [4] - The Zacks Consensus Estimate for ALNY's full-year earnings has increased by 189.3% over the past three months, indicating improved analyst sentiment and a stronger earnings outlook [4] Comparative Analysis - Another outperforming stock in the Medical sector is ALX Oncology Holdings Inc. (ALXO), which has returned 10.8% year-to-date and has a consensus EPS estimate increase of 5.1% over the past three months [5] - Stocks in the Medical - Biomedical and Genetics industry have averaged a gain of 7.7% this year, highlighting that Alnylam Pharmaceuticals is performing better than its industry peers [6] Future Outlook - Investors interested in Medical stocks should monitor Alnylam Pharmaceuticals and ALX Oncology Holdings Inc. for potential continued strong performance [7]

Market Overview - Mid-cap stocks advanced in Q3, with the Russell Midcap Index returning 5.3%, driven by monetary policy shifts and stabilizing earnings [2] - Value stocks outperformed growth stocks, with the Russell Midcap Value Index returning 6.2% compared to 2.8% for the Russell Midcap Growth Index [2] Policy and Sentiment - Investor sentiment improved due to the passage of the One Big Beautiful Bill and progress on trade agreements, reducing policy uncertainty [3] - Earnings estimates stabilized, particularly in technology and AI sectors, despite some economic segments remaining weak [3] Portfolio Performance - The ClearBridge Mid Cap Strategy outperformed its benchmark, with strong stock selection in consumer staples and health care [4] - Performance Food Group and Casey's General Stores were key contributors, benefiting from strategic initiatives and strong execution [4] Sector Contributions - Health care was a significant driver of outperformance, with companies like argenx and Alnylam Pharmaceuticals showing strong results [5] - AppLovin's stock rallied due to excitement around its new e-commerce business, indicating potential for cash flow growth [6] Challenges - Stock selection in consumer discretionary and materials sectors posed challenges, with Chewy and Crown Holdings underperforming [7][8] New Positions - A new position was initiated in QXO, a building materials distribution platform, expected to consolidate the industry and improve efficiency [9] - Bio-Techne was also added to the portfolio, capitalizing on recent weakness and offering durable revenue streams [10] Exits - The position in ATS Corporation was exited due to leadership changes raising concerns about future performance [11] Outlook - The outlook for mid-cap equities remains constructive, with expectations for selective stock picking amid potential volatility [13] - The focus will be on businesses with competitive advantages and resilient cash flows [14] Portfolio Highlights - The ClearBridge Mid Cap Strategy saw contributions from 10 of 11 sectors, with IT and industrials being the largest contributors [16] - Stock selection in consumer staples, IT, and health care sectors positively impacted performance, while consumer discretionary and materials sectors detracted [17]

Core Insights - Alnylam Pharmaceuticals is a leader in RNA interference (RNAi) therapeutics, focusing on treatments for rare diseases and cardiovascular conditions [1][6] - The company's revenue growth is driven by a diverse product lineup, including key drugs like Amvuttra, Givlaari, and Oxlumo [1][6] - Alnylam is conducting the ZENITH global Phase 3 trial for zilebesiran to advance its cardiovascular research [1] Financial Performance - In the first half of 2025, Alnylam's rare disease drugs generated $236.8 million in revenues, marking a 16% increase from the previous year [4] - The company has a negative price-to-earnings (P/E) ratio of -185.46 and a high debt-to-equity ratio of 5.18, indicating financial challenges [4][6] - Despite these challenges, Alnylam's current ratio of 2.80 suggests a strong ability to cover short-term liabilities [5][6] Product Development - Amvuttra has received approval in the U.S. and EU for treating polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis and ATTR amyloidosis with cardiomyopathy (ATTR-CM) [3] - The success of Amvuttra is attributed to new patient initiations and transitions from Onpattro, Alnylam's first FDA-approved drug for hATTR amyloidosis [3]

Core Insights - Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is recognized as one of the top biotech stocks to invest in, with RBC Capital maintaining an Outperform rating and increasing its price target from $435 to $500 due to strong sales data for Amvuttra [1][2] Sales Performance - Amvuttra generated $167 million in revenues in August, marking a 17% increase from July, a 40% growth from June, and a 238% spike from February until the launch of cardiomyopathy (CM) [2] - RBC Capital projects that Amvuttra's peak sales could reach $9.3 billion, up from an earlier estimate of $7.9 billion [2] Financial Guidance - The firm anticipates that Alnylam Pharmaceuticals could raise its TTR guidance by approximately $300 million, bringing it to around $2.5 billion [2] Company Overview - Alnylam Pharmaceuticals is a leading biopharmaceutical company specializing in RNA interference (RNAi) treatments, with several FDA-approved medications for rare genetic diseases [3]

Alnylam Pharmaceuticals (NASDAQ:ALNY) has pulled a television ad for its drug Amvuttra (vutrisiran) after the U.S. FDA determined the spot was misleading. Amvuttra is approved for two heart conditions, hereditary transthyretin-mediated amyloidosis (ATTR-CM) and polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN). ...

Alnylam Pharmaceuticals has stopped airing a TV commercial for its new heart medicine, a sign that the Trump administration’s crackdown on the industry’s ubiquitous drug ads is having an impact on the media landscape https://t.co/kyLputpMGE ...